U.S. markets closed
  • S&P Futures

    4,699.00
    +14.00 (+0.30%)
     
  • Dow Futures

    35,791.00
    +78.00 (+0.22%)
     
  • Nasdaq Futures

    16,383.00
    +65.00 (+0.40%)
     
  • Russell 2000 Futures

    2,262.70
    +8.80 (+0.39%)
     
  • Crude Oil

    72.03
    -0.02 (-0.03%)
     
  • Gold

    1,785.70
    +1.00 (+0.06%)
     
  • Silver

    22.55
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1278
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.4800
    +0.0460 (+3.21%)
     
  • Vix

    21.89
    -5.29 (-19.46%)
     
  • GBP/USD

    1.3242
    -0.0000 (-0.00%)
     
  • USD/JPY

    113.5070
    -0.0330 (-0.03%)
     
  • BTC-USD

    50,824.96
    +62.57 (+0.12%)
     
  • CMC Crypto 200

    1,312.61
    -8.67 (-0.66%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,760.77
    +305.17 (+1.07%)
     

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

·2 min read
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).